Lake Street initiated coverage on Ensysce Biosciences with a new price target
$ENSC
Biotechnology: Pharmaceutical Preparations
Health Care
Lake Street initiated coverage of Ensysce Biosciences with a rating of Buy and set a new price target of $4.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/30/2021 | $4.00 | Buy | Lake Street |
8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)
SCHEDULE 13G/A - Ensysce Biosciences, Inc. (0001716947) (Subject)
10-Q - Ensysce Biosciences, Inc. (0001716947) (Filer)
4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)
4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)
4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)
Lake Street initiated coverage of Ensysce Biosciences with a rating of Buy and set a new price target of $4.00
New York, NY, March 13, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Biosciences, Inc. (NASDAQ:ENSC). The update note includes information on Ensysce Biosciences' business model, services, industry, financial results, valuation, and risks. The update note is available below. Ensysce March 2025 Update Note Highlights from the note include: Ensysce Biosciences Advances Strategic Initiatives and Clinical Programs: Ensysce Biosciences reported robust operational advancements for the fiscal year ended December 31
NEW YORK, March 3, 2025 /PRNewswire/ -- Today's Marketplace (TMP) is proud to announce a featured interview with Ensysce Biosciences (NASDAQ:ENSC) CEO Dr. Lynn Kirkpatrick and Dr. Neel Pathak, DS, Program Director with Creighton University. The doctors joined TMP's host Jane King to discuss the ongoing issues with opioids for pain management and how "clever chemistry" is being used to introduce safer opioids that are less prone to accidental overdose and abuse. "Our team uses what I like to call 'clever chemistry' to create the next generation of opioids."The full interview can be viewed online here. "[Unfortunately,] opioids are still being prescribed for pain
~ Positive Phase 1b Data Confirms Overdose Protection for Highest Dosage Form of PF614-MPAR ~ SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced interim data from its second clinical trial to evaluate PF614-MPAR for overdose protection. Clinical study PF614-MPAR-102, ‘A Single and Multiple Dose Study to Evaluate the Pharmacokinetics of Oxycodone and PF614 when PF614 Capsule is Co‑Administered with Nafamostat as a Combination of Immediate Release Solutio